⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 29, 2026

RNA targeting therapy for a prenatally enriched potassium channel associated with severe childhood epilepsy and premature death.

Sean R Golinski Karla Soriano Alex C. Briegel Madeline C Burke Sheng Tang Gemma L Carvill Emma Sherrill Claudia Lentucci Timothy W. Yu Tojo Nakayama Ruilong Hu Richard S Smith

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the therapeutic potential of RNA targeting therapy for a potassium channel linked to severe childhood epilepsy.
Utilized patient-derived induced excitatory and inhibitory neurons to assess neuronal activity.
Applied antisense oligonucleotide (ASO) knockdown techniques to evaluate current-evoked firing in mid-gestation primary human neurons.
ASO knockdown significantly reduced current-evoked firing in neurons, indicating a possible target for therapy.
Neuronal stimulation led to measurable changes in spiking output, supporting therapeutic intervention before infantile encephalopathy onset.

Implication

Investigates RNA targeting therapy on potassium channel effects in neurons, suggesting an early treatment approach.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Golinski et al. (2026) studied this question.

synapsesocial.com/papers/69f5949771405d493afff759 https://doi.org/10.1038/s41467-026-72334-7

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Targeting heterozygous dominant negative variant of KCNA2 using Gapmer ASO for the treatment of drug-resistant epilepsy2024 · 1 citations
2Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathyOriginal Research · 2026 · 13 citations
3Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus (P10-11.009)Case Report · 2026
4At the forefront of gene-based therapies in dravet syndromeHuman Clinical Trial · 2026
5Individualized Antisense Oligonucleotides for SCN2A Related Developmental Epileptic Encephalopathy2025 · 5 citations